PRESENTATION · Mar 2026 · PDF

BBIO-BBP-418-MDA-2026-High-Throughput-Assay-for-Ribitol-Response-Across-FKRP-Variants

PRESENTATION · Mar 2026 · PDF

BBIO-BBP-418 – MDA 2026 – Real-World Insights into LGMD

PRESENTATION · Mar 2026 · PDF

BBIO-BBP-418 – MDA 2026 – Additional Data from Phase 3 FORTIFY Interim Analysis

PRESENTATION · Mar 2026 · PDF

BBIO-BBP-418 – MDA 2026 – LGMD2IR9 Health Outcomes Mode

PRESENTATION · Mar 2026 · PDF

BBIO-BBP-418 – MDA 2026 – Journey of BBP-418

PRESENTATION · Mar 2026 · PDF

BBIO-BBP-418 – MDA 2026 – Systematic Literature Review in LGMD2IR9

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- Vutisiran HCRU and discontinuation

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- D28 sTTR association with CVMCVH

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- Atrial fibrillation at baseline and clinical outcomes

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- ACM and ACMCVH Subgroup Analysis